Search research articles
Contact Us
Filters
Showing results (91-100 of 137) with videos related to
Page
of 14
Sort By:
Journal for Immunotherapy of Cancer
|
May 22, 2021
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
Chantal Saberian, Rodabe N Amaria, Amer M Najjar, et al.
Cancer Immunology Research
|
September 3, 2016
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
David B Page, Jianda Yuan, David Redmond, et al.
Cancer Discovery
|
May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Journal for Immunotherapy of Cancer
|
October 12, 2018
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
Adi Diab, Helen Gogas, Shahneen Sandhu, et al.
Cancer Discovery
|
March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma
Cara Haymaker, Daniel H Johnson, Ravi Murthy, et al.
Nature Medicine
|
August 29, 2006
Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation
Johannes L Zakrzewski, Adam A Kochman, Sydney X Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Journal for Immunotherapy of Cancer
|
February 27, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation
Chantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 137) with videos related to
Sort By:
Page
of 14
Journal for Immunotherapy of Cancer
|
May 22, 2021
Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
Chantal Saberian, Rodabe N Amaria, Amer M Najjar, et al.
Cancer Immunology Research
|
September 3, 2016
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
David B Page, Jianda Yuan, David Redmond, et al.
Cancer Discovery
|
May 23, 2020
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, et al.
Journal for Immunotherapy of Cancer
|
October 12, 2018
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results
Adi Diab, Helen Gogas, Shahneen Sandhu, et al.
Cancer Discovery
|
March 12, 2021
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma
Cara Haymaker, Daniel H Johnson, Ravi Murthy, et al.
Nature Medicine
|
August 29, 2006
Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation
Johannes L Zakrzewski, Adam A Kochman, Sydney X Lu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)
Adi Diab, Paolo A Ascierto, Michele Maio, et al.
Journal for Immunotherapy of Cancer
|
February 27, 2021
Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation
Chantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, et al.
Page
of 14